(QNRX) – StreetInsider.com Reports
-
Quoin Pharmaceuticals Ltd (QNRX) Misses Q4 EPS by 208c
-
Quoin Pharmaceuticals Ltd (QNRX) Prices 4.06M Share Offering at $1.60/sh
-
Quoin Pharmaceuticals (QNRX) Climbs 140% After Announcing FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
-
Quoin Pharmaceuticals (QNRX) Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
-
Quoin Pharmaceuticals Ltd (QNRX) Announces 2.09M Share and Warrant Offering
-
Quoin Pharmaceuticals (QNRX) Announces FDA Clearance of Clinical Optimization Plan for QRX003
-
Quoin Pharmaceuticals (QNRX) Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
-
Quoin Pharmaceuticals, Ltd. (QNRX) Misses Q1 EPS by 189c
-
Ladenburg Thalmann Downgrades Quoin Pharmaceuticals (QNRX) to Neutral
-
Quoin Pharmaceuticals, Ltd. (QNRX) Tops Q4 EPS by 10c
-
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.26%
-
Quoin Pharmaceuticals Ltd (QNRX) Prices $7M Share and Warrant Offering at $1/sh
-
Quoin Pharmaceuticals Ltd (QNRX) Announces $10M Stock and Warrant Offering
-
Quoin Pharmaceuticals (QNRX) PT Lowered to $8 at Ladenburg Thalmann
-
Quoin Pharmaceuticals (QNRX) PT Lowered to $15 at JMP Securities
-
Quoin Pharmaceuticals, Ltd. (QNRX) Reports Q2 Loss of $3.24/sh
-
Quoin Pharmaceuticals (QNRX) Prices $16.8 Million Upsized Public Offering of ADSs, Warrants
-
Quoin Pharmaceuticals Ltd (QNRX) and Endo Ventures (ENDP) Enter Exclusive Distribution and Supply Agreements
-
Endo International (ENDP) Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
-
Quoin Pharmaceuticals (QNRX) Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price
-
Quoin Pharmaceuticals Ltd (QNRX) Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China
-
Quoin Pharmaceuticals (QNRX) Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University
-
Ladenburg Thalmann Starts Quoin Pharmaceuticals (QNRX) at Buy
-
Pre-Open Stock Movers 04/25: PS Business Parks and Twitter Jump on Deal News; Axsome Sinks on Expected CRL (more...)
-
Quoin Pharmaceuticals Ltd (QNRX) Announces FDA Clearance of IND for QRX003
-
Quoin Pharmaceuticals Ltd (QNRX) Targets Approvals for QRX003 in Netherton Syndrome in 2024
-
Quoin Pharmaceuticals Ltd (QNRX) Submits QRX003 IND for Netherton Syndrome
-
Quoin Pharmaceuticals (QNRX) Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome
-
Quoin Pharmaceuticals Ltd (QNRX) Announces Exclusive Distribution Agreement with ER-Kim for QRX003
-
Quoin Pharmaceuticals Ltd (QNRX) Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome
-
Maxim Group Starts Quoin Pharmaceuticals (QNRX) at Buy
-
Pre-Open Stock Movers 12/15: (QNRX) (GMTX) (GRTX) Higher; (RBLX) (LESL) (MGNI) Lower (more...)
-
Quoin Pharmaceuticals (QNRX) Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome
-
JMP Securities Starts Quoin Pharmaceuticals (QNRX) at Market Outperform
-
Quoin Pharmaceuticals Ltd (QNRX) Appoints Gordon Dunn as CFO
-
Quoin Pharmaceuticals Ltd (QNRX) Announces Exclusive License from Queensland University of Technology, Australia
-
Quoin Pharmaceuticals (QNRX) Completes Merger with Cellect Biotech, Commences Trading Under New Ticker
Back to QNRX Stock Lookup